Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Off-Label Wish List: Industry Groups Want US FDA's Guidances To Do More

Executive Summary

Sponsors and payers question guidances' scope and potential audiences, and wonder if the agency couldn't just perform some retrospective audits of off-label communication to speed things up.

You may also be interested in...



Off-Label Discussion, But No Additions, For House User Fee Bill

Several Republicans remain interested in expanding off-label communications, suggesting the issue could come up outside the user fee context, potentially as part of future drug pricing discussions.

Label Expansion: Could Clinical Experience Data Find Supplement Work-Around?

Friends of Cancer Research seeks way of allowing high-quality efficacy data into label when supplemental NDA is not feasible.

Label Expansion: Could Clinical Experience Data Find Supplement Work-Around?

Friends of Cancer Research seeks way of allowing high-quality efficacy data into label when supplemental NDA is not feasible.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS120121

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel